NR3C1 and glioblastoma: Genome editing is a powerful approach for creating custom alterations to the genome, as evidenced by the recent entrance of zinc finger nucleases into clinical trials for disruption of the HIV-1 co-receptor CCR521 and disruption of the glucocorticoid receptor in T cells for glioblastoma treatment.